Skip to main content

Table 5 Clinical Outcomes of the Study Patients with and without CMV Reactivation

From: Cytomegalovirus reactivation in immunocompetent mechanical ventilation patients: a prospective observational study

  Overall CMV Reactivation  
  N = 71 Yes (n = 13, 18.3%) No (n = 58, 81.7%) P
Complications, n (%)&a 54 (76.1) 13 (100) 41 (70.7) 0.06
Blood Transfusion in ICU, n (%) 52 (73.2) 12 (92.3) 40 (69.0) 0.17
Length of IMV (d)b 13 (8–20) 25 (20–45) 10 (8–18)  < 0.01
Hospitalization Expenses (million/¥)a 0.18 (0.11–0.26) 0.35 (0.35–0.23) 0.16 (0.11–0.23) 0.02
Length of Hospital Stay (d) 29 (17–50) 50 (27–61) 28 (17–41) 0.10
ICU Length of Stay (d)b 14 (9–20) 27 (20–45) 12 (8–18)  < 0.01
28 day All-Cause Mortality, n (%) 17 (23.9) 5 (38.5) 12 (20.7) 0.32
90 day All-Cause Mortality, n (%)b 20 (28.2) 9 (69.2) 11 (19.0)  < 0.01
  1. aP < 0.05; bP < 0.01; Continuous variables were expressed as Mean ± SD or Median (IQRs); Bold font indicates the comparisons with statistical significance; &At least one of the following complications—urinary tract infection, ventilator-associated pneumonia, gastric hemorrhage, disseminated intravascular coagulation, or acute heart failure; IMV Invasive Mechanical Ventilation